<DOC>
	<DOC>NCT02914236</DOC>
	<brief_summary>Evaluation of the Aerin Medical Device used for the treatment of nasal obstruction.</brief_summary>
	<brief_title>Treatment of Nasal Airway Obstruction Using the Aerin Medical Device</brief_title>
	<detailed_description>This is a non-significant risk, prospective, multi-center, non-randomized study to evaluate the safety and efficacy of the Aerin Medical device (Vivaer Stylus) when used to deliver radiofrequency (RF) energy to the nasal valve area to improve symptoms in those diagnosed with nasal airway obstruction.</detailed_description>
	<mesh_term>Airway Obstruction</mesh_term>
	<mesh_term>Nasal Obstruction</mesh_term>
	<criteria>Seeking treatment for nasal obstruction and willing to undergo an officebased procedure NOSE score of â‰¥ 60 at Baseline Nasal valve is a primary or significant contributor to the subject's nasal obstruction as determined by the study investigator (based on clinical presentation, physical examination, nasal endoscopy, etc.) and the subject has a positive response to any of the following temporary measures (based on patient history or office exam): Use of external nasal dilator strips (e.g., Breathe Right Strips) QTip test (manual intranasal lateralization) Use of nasal stents Cottle Maneuver (manual lateral retraction of the cheek) Prior surgical treatment of the nasal valve Rhinoplasty, septoplasty, inferior turbinate reduction or other surgical nasal procedures within the past twelve (12) months Chronic sinusitis, recurrent sinusitis, or allergies leading to nasal obstruction Septal deviation, turbinate hypertrophy, polyps, or ptotic nose tip believed to be a significant contributor to the subject's nasal obstruction symptoms Known or suspected allergies or contraindications for any general or local anesthetic agents and / or any antibiotic medications Known or suspected to be pregnant, or is lactating Other medical conditions which in the opinion of the investigator could predispose the subject to poor wound healing or increased surgical risk</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Nasal valve</keyword>
	<keyword>Nasal airway obstruction</keyword>
</DOC>